MOONLAKE IMMUNOTHERAPEUTICS

NASDAQ: MLTX (MoonLake Immunotherapeutics)

Last update: 24 May, 2023, 2:17AM

27.35

0.26 (0.96%)

Previous Close 27.09
Open 27.10
Volume 1,135,950
Avg. Volume (3M) 372,231
Market Cap 1,193,950,592
Price / Book 3.87
52 Weeks Range
4.48 (-83%) — 29.59 (8%)
Earnings Date 12 May 2023
Diluted EPS (TTM) -2.30
Total Debt/Equity (MRQ) 18.32%
Current Ratio (MRQ) 21.11
Operating Cash Flow (TTM) -139.78 M
Levered Free Cash Flow (TTM) -102.40 M
Return on Assets (TTM) -19.85%
Return on Equity (TTM) -30.64%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bullish Mixed
Biotechnology (Global) Bullish Mixed
Stock MoonLake Immunotherapeutics Bullish Bearish

AIStockmoo Score

1.3
Analyst Consensus -1.5
Insider Activity NA
Price Volatility 2.0
Technical Moving Averages 2.5
Technical Oscillators 2.0
Average 1.25

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
MLTX 1 B - - 3.87
ROIV 20 B - - 4.43
BMRN 12 B - 23.58 1.90
VRTX 122 B - 31.44 6.10
TECH 9 B 0.56% 108.53 4.66
CRSP 5 B - - 2.65

MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Sector Healthcare
Industry Biotechnology
Investment Style Mid Growth
% Held by Insiders 15.34%
% Held by Institutions 96.70%
52 Weeks Range
4.48 (-83%) — 29.59 (8%)
Price Target Range
10.00 (-63%) — 35.00 (27%)
High 35.00 (Oppenheimer, 27.97%) Buy
Median 27.50 (0.55%)
Low 10.00 (Goldman Sachs, -63.44%) Sell
Average 24.00 (-12.25%)
Total 4 Buy, 1 Hold, 1 Sell
Avg. Price @ Call 17.33
Firm Date Target Price Call Price @ Call
Oppenheimer 24 Feb 2026 35.00 (27.97%) Buy 18.07
BTIG 23 Feb 2026 30.00 (9.69%) Buy 18.07
09 Feb 2026 24.00 (-12.25%) Buy 15.75
Needham 23 Feb 2026 25.00 (-8.59%) Buy 18.07
RBC Capital 20 Feb 2026 12.00 (-56.12%) Hold 18.07
HC Wainwright & Co. 03 Feb 2026 32.00 (17.00%) Buy 15.37
09 Jan 2026 32.00 (17.00%) Buy 18.49
Goldman Sachs 15 Jan 2026 10.00 (-63.44%) Sell 16.35

No data within this time range.

Date Type Details
02 Feb 2026 Announcement MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
02 Feb 2026 Announcement MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
08 Jan 2026 Announcement MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
08 Jan 2026 Announcement MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
15 Dec 2025 Announcement New SueWallSt Podcast Covers MoonLake Immunotherapeutics (MLTX) Class Action
12 Dec 2025 Announcement MoonLake Immunotherapeutics (MLTX) Shareholders Get Answers in Latest SueWallSt Podcast
09 Dec 2025 Announcement SueWallSt Podcast Series Launches With Focus on MoonLake Immunotherapeutics (MLTX) Fraud Allegations
08 Dec 2025 Announcement Shareholders SueWallSt in New Class Action Against MoonLake Immunotherapeutics - Act Now
08 Dec 2025 Announcement SueWallSt Podcast Series Launches With Focus on MoonLake Immunotherapeutics (MLTX) Fraud Allegations
05 Dec 2025 Announcement MoonLake Immunotherapeutics (MLTX) Shareholders Get Answers in Latest SueWallSt Podcast
04 Dec 2025 Announcement Tune Into the SueWallSt Podcast: MoonLake Immunotherapeutics (MLTX) Lawsuit Explained
03 Dec 2025 Announcement Tune Into the SueWallSt Podcast: MoonLake Immunotherapeutics (MLTX) Lawsuit Explained
02 Dec 2025 Announcement Latest SueWallSt Podcast: What MLTX Investors Need to Know About the Lawsuit
25 Nov 2025 Announcement MoonLake Immunotherapeutics (MLTX) Shareholders Get Answers in Latest SueWallSt Podcast
24 Nov 2025 Announcement New SueWallSt Podcast Covers MoonLake Immunotherapeutics (MLTX) Class Action
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria